CLL

Rituxacin, manufactured by the Novartis Pharmaceutical company, has had at least a 50% success rate in putting B cell-CLL patients into complete remission. In the past, it had been used on B cell-lymphoma. My brother-in-law has B-cell CLL and was treated with Rituxacin in November-December 1999 and is now in complete remission.